Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Assertio Therapeutics ( (ASRT) ) just unveiled an update.
On October 7, 2025, Spectrum Pharmaceuticals, a subsidiary of Assertio Holdings, and Hanmi Pharmaceutical amended their supply agreement for ROLVEDON drug substance, establishing long-term pricing with a mid-single digit percentage reduction. The amendment allows for price adjustments based on market volume and cost increases, requiring Spectrum’s consent for manufacturing changes, and mandates an annual forecasted purchase plan without minimum purchase requirements.
The most recent analyst rating on (ASRT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.
Spark’s Take on ASRT Stock
According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.
The overall stock score of 54 reflects significant financial challenges, despite positive technical indicators and some positive developments from the earnings call. The negative P/E ratio and lack of dividend yield further weigh down the score.
To see Spark’s full report on ASRT stock, click here.
More about Assertio Therapeutics
Assertio Holdings, Inc. operates in the pharmaceutical industry through its subsidiary Spectrum Pharmaceuticals, Inc., focusing on the supply of drug substances such as ROLVEDON.
Average Trading Volume: 264,489
Technical Sentiment Signal: Sell
Current Market Cap: $85.46M
Learn more about ASRT stock on TipRanks’ Stock Analysis page.